Anastasia Aleksandrovna Rusakova

Ms. Anastasia Aleksandrovna Rusakova

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
APAleksander A. Pushkov
Aleksander A. Pushkov
IZIlya Sergeevich Zhanin
Ilya Sergeevich Zhanin
Daria ChudakovaDaria Chudakova
Daria Chudakova
ARAnastasia Aleksandrovna Rusakova
Anastasia Aleksandrovna Rusakova
DDDmitry S. Demianov
Dmitry S. Demianov
KSKirill Savostyanov
Kirill Savostyanov
Hypophosphatasia (HPP) is a rare hereditary metabolic disorder caused by nucleotide variants (NVs) in the ALPL gene, leading to a deficiency of tissue-nonspecific alkaline phosphatase (TNSALP). HPP has a variable clinical presentation (such as impaired mineralization of bones and teeth, respiratory dysfunctions, muscle weakness, muscle and bone pain, growth deficiency, nephrocalcinosis, seizures, encephalopathy, intracranial hypertension, and intellectual disability) overlapping with other disorders which often delays a correct diagnosis. In this study, we present the results of a two-center (Moscow and Saint Petersburg) selective screening program conducted in the period 2022–2026 in Russia, based on next-generation sequencing (NGS) of 4912 patients with suspected HPP. Each center used its own NGS gene panel. In Moscow, causal nucleotide variants in ALPL were found in 9.45% of patients, and variants in other genes from the panel were identified in 9.77% of patients. The selection criteria for the screening evolved during the study, resulting in a higher diagnostic yield. In Saint Petersburg, causal variants in ALPL were found in 3.5% of patients. The most frequent ALPL variant was c.571G>A (28%), which is consistent with its founder effect in Northern Europe. In the differential diagnosis gene panel, pathogenic or likely pathogenic variants were most commonly found in the COL1A2, COL1A1, and CASR genes, highlighting the phenotypic overlap of HPP with osteogenesis imperfecta and related disorders, and underscoring the value of targeted NGS for resolving diagnostic uncertainty in HPP. Overall, this study provides the most comprehensive data on the genetics of HPP in the Russian population to date.

5 July 2026 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
ARAnastasia Aleksandrovna Rusakova
Anastasia Aleksandrovna Rusakova
NMN. N. Mazanova
N. N. Mazanova
APAleksander Pushkov
Aleksander Pushkov
GMG. B. Movsisyan
G. B. Movsisyan
DDD. S. Demianov
D. S. Demianov
KSKirill Savostyanov
Kirill Savostyanov
Introduction . Niemann-Pick disease type A (NPD type A) is the most severe form of acid sphingomyelinase deficiency, a rare inherited disorder of the lysosomal storage disorders with autosomal recessive inheritance caused by biallelic pathogenic variants in the SMPD1 gene. Since 2023, enzyme replacement therapy with olipudase alfa has been used to treat patients with NPD in Russia. This therapy does not alter the prognosis for neurological forms of the disease, as it does not penetrate the blood-brain barrier. Therefore, the only effective treatment, along with symptomatic therapy, for the systemic manifestations of NPD type A is hematopoietic stem cell transplantation, which does not prevent central nervous system damage. Early laboratory diagnostics using biochemical and molecular genetic diagnostic methods are crucial for timely diagnosis and treatment of patients with this form of the disease. Aim : to describe intrafamilial polymorphism of clinical symptoms of NPD, type A using the example of two siblings from the same family. Materials and methods . Clinical observation and diagnostics were conducted at the National Medical Research Center for Children’s Health of the Russian Ministry of Health from 2012 to 2026 in a single family in which the first proband with clinical symptoms characteristic of NBP type A was identified in 2012. Acid sphingomyelinase activity was measured in dried blood spots using tandem mass spectrometry, and nucleotide variants in the SMPD1 gene were identified using Sanger sequencing. Familial segregation analysis was performed for the proband and eight family members. Results . Diagnosis of the first proband revealed a significant decrease in acid sphingomyelinase activity in the patient’s spinal cord. Sequencing revealed the presence of two pathogenic heterozygous variants in the SMPD1 gene: c.996del ( p.Phe333Serfs52 ) and c.1252C > T ( p.Arg418 ). Carriage of the pathogenic causative variants in the SMPD1 gene was confirmed in the parents. The second proband was diagnosed on the second day of life. As a result of the timely diagnosis, immunotherapy (bone marrow transplant) was prescribed, which determined the child’s prognosis. Conclusion . Using two siblings from the same family as an example, polymorphism in the clinical symptoms of NPD type A was demonstrated. Early diagnosis of this form of the disease significantly improves the prognosis and enables timely initiation of therapy.